CRCT1 and breast cancer: The amplification of 1q21.3 occurs in all the BC subtypes [29], which is consistent with the amplification of the HRNR, FLG2, CRCT1, and KPRP genes in ER+, HER2+, and TN BCs (Figure 2A), suggesting that taxifolin or other mechanisms inducing HRNR, FLG2, CRCT1, and KPRP expressions could also be used as targeted therapies for TNBCs.